Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) fell short of the market’s revenue expectations in Q2 CY2025, with sales falling 4.1% year on year to $378 million. The company’s full-year revenue guidance of $1.49 billion at the midpoint came in 5% below analysts’ estimates. Its non-GAAP profit of $1.57 per share was 6.3% below analysts’ consensus estimates.
Lantheus Holdings (LNTH) Q2 2025 earnings miss estimates, revenue down 4.1%. Shares drop 20.8% as weak guidance raises concerns. FDA accepts NDA for PYLARIFY upgrade.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
will be reporting earnings this Wednesday before market hours. Here’s what investors should know.
Lantheus Holdings (LNTH) is a standout value stock with strong financials, low P/E ratios, and high profitability, making it an attractive pick for value investors.
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
fell 7.7% in the morning session after the stock hit a new 52-week low amid persistent investor concerns over rising competition and the company's recent financial results.
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.
LANTHEUS HOLDINGS INC (NASDAQ:LNTH) is an undervalued healthcare stock with strong profitability, financial health, and reasonable growth potential, making it a candidate for value investors.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Lantheus (NASDAQ:LNTH) and the best and worst performers in the medical devices & supplies - imaging, diagnostics industry.
Lantheus Holdings (NASDAQ:LNTH) presents an undervalued opportunity with strong profitability, financial health, and reasonable growth, making it a candidate for value investors.
Lantheus Holdings (LNTH) is an undervalued stock with strong profitability, financial health, and growth potential, trading below industry averages. A solid pick for value investors.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $372.8 million. The company’s full-year revenue guidance of $1.57 billion at the midpoint came in 1.8% below analysts’ estimates. Its non-GAAP profit of $1.53 per share was 7.5% below analysts’ consensus estimates.
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
fell 22.2% in the afternoon session after the company reported weak first quarter 2025 results which included a significant miss on full-year EPS guidance and EPS falling short of Wall Street's estimates. Sales were flat, with a slight drop in PYLARIFY mostly offset by small gains in other parts of the business. Operating profit also fell. The real issue was the cut to full-year earnings, now seen at $6.60 to $6.70 per share, well below the $7.00 to $7.20 range it gave before. Overall, this was a softer quarter.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $372.8 million. The company’s full-year revenue guidance of $1.57 billion at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $1.53 per share was 7.5% below analysts’ consensus estimates.
